Parkinson's Drug Nuplazid Priced High; Acadia Aims For Alzheimer's Next
Executive Summary
Acadia Pharmaceuticals Inc. priced its Parkinson's disease psychosis (PDP) drug Nuplazid (pimavanserin) at $1,950 for a 30-day supply, which was significantly higher than Wall Street expected. With the US approval of Nuplazid in PDP in hand, the company is now focused on its development programs for the drug as a treatment for Alzheimer's disease psychosis and Alzheimer's agitation.
You may also be interested in...
Acadia Expects Broad Nuplazid Reimbursement; Pricing Soon
Acadia Pharmaceuticals Inc. has not yet priced its newly approved Parkinson's disease psychosis (PDP) drug Nuplazid (pimavanserin), but anticipates it will be covered by a vast majority of payers. The PDP approval also sets the stage for expanding Nuplazid's use into other indications, including Alzheimer's disease psychosis and agitation.
Acadia's Nuplazid OK'd; A Billion Dollar Parkinson's Drug?
The FDA on April 29 approved Acadia Pharmaceuticals Inc.'s Nuplazid (pimavanserin) as the first product in the US treat hallucinations and delusions associated with Parkinson's disease psychosis. The medicine has the potential to be the company's first billion dollar product.
Focus Turns To Label After Panel Backs Acadia's Nuplazid
If the FDA takes its outside experts' advice, Acadia Pharmaceuticals Inc. could finally be on its way to having a billion dollar drug on the US market: Nuplazid (pimavanserin), a selective inverse agonist of the 5-hydroxytryptamine 2A (5-HT2A) receptor, which the biotech is seeking as a treatment for psychosis associated with Parkinson's disease (PDP).